Starget Pharma Inc.
New Form D on file · 2026-02-03 · the record
What the record says
Trailing twelve months. 716 filings in Biotechnology, totalled by week. The dot is this raise, $16.37M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Company officers on record
Sigal Kalmanson Cusnir is named as Executive Officer on the Form D that Starget Pharma Inc. filed with the SEC on 3 February 2026, one of 2 people that filing names.
Ronen Kalmanson is named as Director on the Form D that Starget Pharma Inc. filed with the SEC on 3 February 2026, one of 2 people that filing names.
2 people named on the filing — 1 holding an executive role and 1 as a director only.
Named as of the 2026-02-03 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Starget Pharma Inc.
- Source Check — verify Sigal Kalmanson Cusnir's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Sigal Kalmanson Cusnir for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Starget Pharma Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Starget Pharma Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.